Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 2/2016

01.06.2016 | Short Communication

Nodal Follicular Lymphomas: A Clinicopathological Study from a Tertiary Care Centre in South India

verfasst von: Divya Supari, Anuradha Ananthamurthy

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to assess the distribution of nodal follicular lymphomas (FL) among various subtypes of non- Hodgkin lymphoma and to study their clinico-pathological features. Clinical details, histomorphology including grading & patterns and immunoprofile of 44 cases were studied. Majority of the cases were grade 1 (61 %) FL. BCL2 positivity was higher in low grade FLs (97 %). An associated diffuse large B cell lymphoma component was seen in 18 % and was present only in conjunction with grade 3 FL. Majority of our patients (76 %) had a high FLIPI score and belonged to the high risk group. Our study showed that the incidence of FLs is much lower in the Indian population (14.5 %) when compared to western studies and majority were of low grade. Although there was complete initial response to treatment, relapse was common and was much higher in low grade FLs with diffuse areas on histology, Ann Arbor stage III/IV and FLIPI scores of 3–5.
Literatur
1.
Zurück zum Zitat Harris NL, Swerdlow SH, Jaffe ES, Ott G, Nathwani BN, Jong D et al (2008) Follicular lymphomas. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) WHO classification of tumours of hematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer (IARC), Lyon, pp 220–226 Harris NL, Swerdlow SH, Jaffe ES, Ott G, Nathwani BN, Jong D et al (2008) Follicular lymphomas. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) WHO classification of tumours of hematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer (IARC), Lyon, pp 220–226
2.
Zurück zum Zitat Biagi JJ, Seymour JF (2002) Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation. Blood 99:4265–4275CrossRefPubMed Biagi JJ, Seymour JF (2002) Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation. Blood 99:4265–4275CrossRefPubMed
3.
Zurück zum Zitat Naresh KN, Srinivas V, Soman CS (2000) Distribution of various subtypes of non Hodgkin’s lymphomas in India: a study of 2773 lymphomas using REAL and WHO classifications. Ann Oncol 11(suppl 1):S63–S67CrossRef Naresh KN, Srinivas V, Soman CS (2000) Distribution of various subtypes of non Hodgkin’s lymphomas in India: a study of 2773 lymphomas using REAL and WHO classifications. Ann Oncol 11(suppl 1):S63–S67CrossRef
4.
Zurück zum Zitat Horning SJ, Rosenberg SA (1984) The natural history of initially untreated low grade non-Hodgkin’s lymphomas. N Engl J Med 311:1471–1475CrossRefPubMed Horning SJ, Rosenberg SA (1984) The natural history of initially untreated low grade non-Hodgkin’s lymphomas. N Engl J Med 311:1471–1475CrossRefPubMed
5.
Zurück zum Zitat Anon (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The non-Hodgkin’s lymphoma classification project. Blood 89:3909–3918 Anon (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The non-Hodgkin’s lymphoma classification project. Blood 89:3909–3918
6.
Zurück zum Zitat Non-Hodgkin’s lymphoma pathologic classification project (1982) National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. Cancer 49:2112–2135CrossRef Non-Hodgkin’s lymphoma pathologic classification project (1982) National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. Cancer 49:2112–2135CrossRef
7.
Zurück zum Zitat Ott G, Katzenberger T, Lohr A et al (2002) Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 99:3806–3812CrossRefPubMed Ott G, Katzenberger T, Lohr A et al (2002) Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 99:3806–3812CrossRefPubMed
8.
Zurück zum Zitat Karube K, Guo Y, Suzumiya J et al (2007) CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features. Blood 109:3076–3079PubMed Karube K, Guo Y, Suzumiya J et al (2007) CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features. Blood 109:3076–3079PubMed
9.
Zurück zum Zitat Eshoa C, Perkins S, Kampalath B, Shidham V, Juckett M, Chang CC (2001) Decreased CD10 expression in grade III and in interfollicular infiltrates of follicular lymphomas. Am J Clin Pathol 115:862–867CrossRefPubMed Eshoa C, Perkins S, Kampalath B, Shidham V, Juckett M, Chang CC (2001) Decreased CD10 expression in grade III and in interfollicular infiltrates of follicular lymphomas. Am J Clin Pathol 115:862–867CrossRefPubMed
10.
Zurück zum Zitat Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, Sehn LH, Shenkier TN, Gascoyne RD, Connors JM (2008) Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. J Clin Oncol 26:5165–5169CrossRefPubMed Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, Sehn LH, Shenkier TN, Gascoyne RD, Connors JM (2008) Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. J Clin Oncol 26:5165–5169CrossRefPubMed
11.
Zurück zum Zitat Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J, Vinnicombe S, Waters R, Rohatiner AZ, Lister TA (2007) Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 25:2426–2433CrossRefPubMed Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J, Vinnicombe S, Waters R, Rohatiner AZ, Lister TA (2007) Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 25:2426–2433CrossRefPubMed
12.
Zurück zum Zitat Federico M, Bellei M, Marcheselli L et al (2009) Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project. J Clin Oncol 27:4555–4562CrossRefPubMed Federico M, Bellei M, Marcheselli L et al (2009) Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project. J Clin Oncol 27:4555–4562CrossRefPubMed
13.
Zurück zum Zitat Hiddemann W, Kneba M, Dreyling M et al (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725CrossRefPubMed Hiddemann W, Kneba M, Dreyling M et al (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725CrossRefPubMed
14.
Zurück zum Zitat McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R et al (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825–2833PubMed McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R et al (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825–2833PubMed
15.
Zurück zum Zitat Plancarte F, Lopez-Guillermo A, Arellinas L et al (2006) Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. Eur J Haematol 76:58–63CrossRefPubMed Plancarte F, Lopez-Guillermo A, Arellinas L et al (2006) Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. Eur J Haematol 76:58–63CrossRefPubMed
Metadaten
Titel
Nodal Follicular Lymphomas: A Clinicopathological Study from a Tertiary Care Centre in South India
verfasst von
Divya Supari
Anuradha Ananthamurthy
Publikationsdatum
01.06.2016
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 2/2016
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-015-0610-6

Weitere Artikel der Ausgabe 2/2016

Indian Journal of Hematology and Blood Transfusion 2/2016 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.